Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Ital J Pediatr ; 50(1): 111, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38831374

ABSTRACT

BACKGROUND: Lysinuric protein intolerance (LPI) is a multi-organ metabolic disorder characterized by the imbalance in absorption and excretion of cationic amino acids like lysine, ornithine and arginine. Infants with LPI typically present with recurrent vomiting, poor growth, interstitial lung disease or renal impairment. The early onset of pulmonary alveolar proteinosis (PAP) has been reported to be associated with a severe form of LPI. Treatment of PAP most commonly consists of whole-lung lavage (WLL) and in autoimmune PAP, granulocyte-macrophage colony stimulating factor (GM-CSF) administration. Nevertheless, GM-CSF therapy in LPI-associated PAP has not been scientifically justified. CASE PRESENTATION: We describe the case of an 8-month-old infant presenting with respiratory failure due to LPI associated with PAP, who was twice treated with WLL; firstly, while on veno-venous ECMO assistance and then by the use of a selective bronchial blocker. After the two treatments with WLL, she was weaned from daytime respiratory support while on initially subcutaneous, then on inhaled GM-CSF therapy. CONCLUSIONS: This case supports the notion that GM-CSF therapy might be of benefit in patients with LPI-associated PAP. Further studies are needed to clarify the exact mechanism of GM-CSF in patients with LPI-associated PAP.


Subject(s)
Amino Acid Metabolism, Inborn Errors , Bronchoalveolar Lavage , Granulocyte-Macrophage Colony-Stimulating Factor , Pulmonary Alveolar Proteinosis , Humans , Pulmonary Alveolar Proteinosis/therapy , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Infant , Female , Amino Acid Metabolism, Inborn Errors/therapy , Amino Acid Metabolism, Inborn Errors/complications
2.
Sci Rep ; 12(1): 19759, 2022 11 17.
Article in English | MEDLINE | ID: mdl-36396679

ABSTRACT

Multisystem inflammatory syndrome in children (MIS-C) is a rare, life-threatening complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. MIS-C develops with high fever, marked inflammation and shock-like picture several weeks after exposure to, or mild infection with SARS-CoV-2. Deep immune profiling identified activated macrophages, neutrophils, B-plasmablasts and CD8 + T cells as key determinants of pathogenesis together with multiple inflammatory markers. The disease rapidly responds to intravenous immunoglobulin (IVIG) treatment with clear changes of immune features. Here we present the results of a comprehensive analysis of the complement system in the context of MIS-C activity and describe characteristic changes during IVIG treatment. We show that activation markers of the classical, alternative and terminal pathways are highly elevated, that the activation is largely independent of anti-SARS-CoV-2 humoral immune response, but is strongly associated with markers of macrophage activation. Decrease of complement activation is closely associated with rapid improvement of MIS-C after IVIG treatment.


Subject(s)
COVID-19 , Child , Humans , Immunoglobulins, Intravenous/therapeutic use , SARS-CoV-2 , Complement Activation
3.
European J Pediatr Surg Rep ; 10(1): e107-e110, 2022 Jan.
Article in English | MEDLINE | ID: mdl-35992308

ABSTRACT

Severe abdominal pain and vomiting are common symptoms in children with pediatric multisystem inflammatory syndrome (PIMS). Mesenteric lymphadenitis and aseptic peritonitis are predominantly reported in cases where acute surgical abdomen was suspected and laparotomy was performed at the early stage of the pandemic. These reports generally discouraged surgeons to perform exploration in COVID-19-related cases and medical management was prioritized. Only a few COVID-19-specific surgical cases with intestinal ischemia were published. Here, we report another case of COVID-19-related intestinal ischemia complicated with Meckel's diverticulitis in a non-immunocompromised child who clearly required surgical intervention. In our case, the combination of COVID-19-related vasculitis and low blood pressure episodes may have contributed to this severe outcome.

4.
Eur J Gastroenterol Hepatol ; 16(2): 127-33, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15075984

ABSTRACT

OBJECTIVE: Transforming growth factor beta-1 (TGF-beta 1) is thought to be one of the most important factors affecting the development of fibrotic processes in the liver. AIM: To discover whether endogenously higher TGF-beta 1 production influences the progression and reversibility of liver fibrosis in mice. METHOD: We compared thioacetamide-induced liver fibrosis between wild-type and transgenic mice overexpressing active TGF-beta 1 in the liver. Hepatic fibrosis was detected on histological sections, and fibrotic areas were measured by means of morphometric analysis. We also performed Northern blot hybridisation and gelatine zymography to improve our understanding of the process. RESULTS: The fibrotic process was faster in the transgenic animals, and regression after the withdrawal of the fibrogenic agent was slower. Fibrosis did not disappear completely from the TGF-beta 1 overexpressing mice, even at the endpoint of the experiment. CONCLUSION: Since the increased TGF-beta 1 production in the liver slowed down the regression of the liver fibrosis, the behaviour of these transgenic mice is more similar to the human situation, where cirrhosis is irreversible. We propose that this transgenic model is more suitable for investigating fibrotic liver diseases than the experiments done previously on wild-type rodents.


Subject(s)
Liver Cirrhosis, Experimental/metabolism , Transforming Growth Factor beta/metabolism , Animals , Blotting, Northern/methods , Collagen/metabolism , Female , Gelatinases/metabolism , Liver Cirrhosis, Experimental/pathology , Male , Matrix Metalloproteinases/metabolism , Mice , Mice, Transgenic , RNA, Messenger/analysis , Thioacetamide , Transforming Growth Factor beta1
5.
Pathol Oncol Res ; 2(3): 174-176, 1996.
Article in English | MEDLINE | ID: mdl-11173602

ABSTRACT

Primary central nervous system lymphomas are rather rare, however, their frequency seems to be increasing in both high risk and immunocompetent patients with very poor prognosis. Here we describe a model intracerebrally xenotransplating human non Hodgkin lymphoma cells of B cell origin (HT 58). This offers a unique possibility to study the theraputic response, especially on systemic treatment. Briefly, one million lymphoma cells grew as meningeal tumor mass, infiltrating the brain directly as well as via the perivascular space. The lymphoma cells preserved all the phenotypic characteristics of the source tumor.

SELECTION OF CITATIONS
SEARCH DETAIL
...